/ /

  • linkedin
  • Increase Font
  • Sharebar

    NSAIDs offer potential hope for DR, AMD

    Orlando—Nonsteroidal anti-inflammatory drugs (NSAIDs) are well recognized as potent agents as they block all downstream prostaglandins, have a long history of safety and efficacy, and fare well in extended-release formulations. Recently, there has been a growing body of evidence showing that they have potential in treating cystoid macular edema, said Stephen Kim, MD.

    This evidence has led to various attempts at developing NSAIDs for the treatment of retinal disorders, said Dr. Kim, Vanderbilt University, Nashville, TN.

    The National Eye Institute undertook a study on oral celecoxib to see if it could stabilize or improve vision in patients with age-related macular degeneration (AMD) who are receiving photodynamic therapy (PDT), he said.

    Celecoxib is an anti-inflammatory drug that, in animal studies, had prevented the growth of abnormal blood vessels associated with tumors and with injury to the cornea. With that history, celecoxib might reduce swelling and prevent vessel re-growth in AMD, enhancing the effectiveness of PDT, Dr. Kim said. Results were disappointing and the study was halted, he noted.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results